Add BrightSurf on Google Email

Science News for April 19, 2026


Application of a new combined surgical strategy in spontaneous supratentorial intracerebral hemorrhage

A new combined surgical strategy outperforms conventional methods in treating spontaneous supratentorial intracerebral hemorrhage by enabling rapid ICP reduction and efficient hematoma clearance. This approach showed improved outcomes in selected patients, but further studies are needed to validate its efficacy.

SourceXia & He Publishing Inc.·JournalNeurosurgical Subspecialties·DateApr 19, 2026

Oldest dinosaur tracksite in Northeast Asia discovered: evidence shows large dinosaurs ranges as far as northern Mongolia 120 million years ago

A joint research team has rediscovered a dinosaur tracksite in the Saizhurakh area of northern Mongolia, revealing footprints of both large herbivorous and carnivorous dinosaurs. The site provides clear evidence that large dinosaurs inhabited regions as far north as northern Mongolia during the Early Cretaceous period.

How to remove a metabolic tattoo

A team of Kyoto University researchers found that exposure to high-fat diets induces persistent metabolic stress in killer T cells, but also discovered a pathway for protection through purine metabolism. By recycling xanthine, killer T cells can produce antioxidants to boost their ability to fight tumors.

SourceKyoto University·JournalNature Immunology·TypeExperimental study·DateApr 19, 2026

Continuous-wave-pumped bichromatic dissipative quadratic soliton femtosecond mode-locking

A new approach to ultrafast nonlinear frequency conversion using dissipative quadratic soliton physics enables simultaneous generation of bichromatic femtosecond pulse trains in a single quadratic nonlinear cavity. This innovation offers a scalable and efficient solution for diverse scientific and technological applications.

Dana-Farber Phase 1 study explores toxicity reduction in combination of trastuzumab deruxtecan and olaparib in advanced HER2-expressing malignancies

A phase 1 study found a tolerable dosing schedule with promising activity, with anti-cancer activity seen across various dosing schedules and tumor types. The regimen was selected for further evaluation, offering hope for expanded treatment options for patients with HER2-expressing advanced solid tumors.

A quantum-in-memory stochastic processor for secure and accelerated computing

Researchers have developed a quantum-enhanced in-memory stochastic computing system based on a room-temperature quantum memory, leveraging intrinsic randomness to perform computations securely and efficiently. The system outperforms classical methods in terms of coincidence rates and processing speed.

Turning seawater into green gold: innovative catalyst enables continuous hydrogen production and high-purity mineral recovery

A new catalyst enables continuous hydrogen production and recovers high-purity magnesium hydroxide in seawater electrolysis. The innovation prevents cathode scaling and maintains stability over 5,000 hours., Researchers achieved a purity of 99% for the valuable byproduct Mg(OH)₂.

SourceShanghai Jiao Tong University Journal Center·JournalENGINEERING Energy·TypeNews article·DateApr 19, 2026

‘Fingerprints’ of childhood cancer treatment provide clues that may help mitigate second cancers

Researchers at St. Jude Children's Research Hospital identified therapy-specific mutations that could guide safer treatments among childhood cancer survivors. The study analyzed genetic mutations in subsequent neoplasms of 160 survivors who developed breast, thyroid malignancies and meningiomas after treatment.

SourceSt. Jude Children's Research Hospital·JournalCancer Discovery·TypeExperimental study·DateApr 19, 2026

Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer

A new study found that elisrasib, a next-generation KRAS-G12C inhibitor, demonstrated a favorable safety and tolerability profile. In patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), elisrasib showed promising response rates of 58.8% and disease control rate of 98.5%. The treatment also improved outcomes...